

(FILE 'HOME' ENTERED AT 13:53:22 ON 16 MAY 2003)

FILE 'MEDLINE, BIOSIS, CANCERLIT, LIFESCI, BIOTECHDS, CAPLUS' ENTERED AT 13:53:38 ON 16 MAY 2003

L1 3501 S APOPTO?(5A)MARKER#
L2 466 S L1/TI
L3 288 S L2 AND PY<2001
L4 156 DUP REM L3 (132 DUPLICATES REMOVED)
L5 256 S L2 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGNAN? OR NEOPLAS
L6 247 S L2 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGNAN? OR NEOPLAS
L7 145 S L2 AND (LEUKEMI## OR LEUKAEMI## OR LYMPHOMA# OR MELANOMA# OR
L8 256 S L6 OR L7
L9 144 S L8 AND PY<2001
L10 77 DUP REM L9 (67 DUPLICATES REMOVED)
L11 1476 S L1 AND (CANCER? OR TUMOR? OR TUMOUR? OR MALIGNAN? OR
NEOPLAS?
L12 824 S L1 AND (LEUKEMI## OR LEUKAEMI## OR LYMPHOMA# OR MELANOMA#
OR
L13 303 S L11 AND ANTIBOD?
L14 159 S L12 AND ANTIBOD?
L15 323 S L13 OR L14
L16 179 S L15 AND PY<2001
L17 69 DUP REM L16 (110 DUPLICATES REMOVED)
L18 59 S L17 NOT L10

FILE 'MEDLINE' ENTERED AT 14:48:19 ON 16 MAY 2003

L19 105 S (2000 AND 77 AND 11)/SO
L20 1 S L19 AND MORSI?/AU

FILE 'PCTFULL, USPATFULL, EUROPATFULL' ENTERED AT 15:07:53 ON 16 MAY 2003

L21 546 S APOPTO?(3A)MARKER#
L22 127 S L21(S)ANTIBOD?
L23 91 S L22 AND ((FLOW(W)CYTOMET?) OR (FLUORESC?(2W)MICROSCOP?) OR (
L24 20 S L23 AND PD<20000112

=> log h



Gateway

your entrance to the
knowledge resources of the
National Library of Medicine

New Search

Concept Details

[Overview](#)[What's New](#)[Help](#)[FAQ](#)[Other NLM
Resources](#)[Ordering Info.](#)[Clinical Alerts](#)[ClinicalTrials.gov](#)[HSTAT](#)[LOCATORplus](#)[MEDLINEplus](#)[PubMed](#)[TOXNET](#)

Genes, ras

Family of retrovirus-associated DNA sequences (ras) originally isolated from Harvey (H-ras, Ha-ras, rasH) and Kirsten (K-ras, Ki-ras, rasK) murine sarcoma viruses. Ras genes are widely conserved among animal species and sequences corresponding to both H-ras and K-ras genes have been detected in human, avian, murine, and non-vertebrate genomes. The closely related N-ras gene has been detected in human neuroblastoma and sarcoma cell lines. All genes of the family have a similar exon-intron structure and each encodes a p21 protein.

[Related
Concepts](#)[View MeSH
Information](#)[Add to
Search](#)

using Connector:

AND



or

[Cancel](#)

- ☐ Main point of item
☐ Do not explode this term

With Subheadings:

[Subheading
Definitions](#)

- | | |
|---------------------------------------|--|
| <input type="checkbox"/> drug effects | <input type="checkbox"/> immunology |
| <input type="checkbox"/> ethics | <input type="checkbox"/> physiology |
| <input type="checkbox"/> genetics | <input type="checkbox"/> radiation effects |

MeSH Tree 1

- ▶ All MeSH Categories
 - ▶ Biological Sciences (MeSH Category)
 - ▶ Genetic Structures
 - ▶ Genes
 - ▶ Oncogenes
 - ▶ Proto-Oncogenes
 - ▶ Genes, abl
 - ▶ Genes, bcl-1
 - ▶ Genes, bcl-2
 - ▶ Genes, erbA
 - ▶ Genes, erbB
 - ▶ Genes, fms
 - ▶ Genes, fos
 - ▶ Genes, jun
 - ▶ Genes, mos
 - ▶ Genes, myb
 - ▶ Genes, myc
 - ▶ **Genes, ras**
 - ▶ Genes, rel
 - ▶ Genes, sis
 - ▶ Genes, src

[Contact Us](#)

[U.S. National Library of Medicine](#) | [National Institutes of Health](#) | [Department of Health & Human Services](#) | [Freedom of Information Act](#) | [Copyright & Privacy](#)

anti-p21 antibody (sc-397-G, Santa Cruz Biotechnology).

WEST**End of Result Set**

Generate Collection

Print

L10: Entry 2 of 2

File: USPT

Sep 28, 1999

US-PAT-NO: 5958892

DOCUMENT-IDENTIFIER: US 5958892 A

** See image for Certificate of Correction **

TITLE: 2-methoxyestradiol-induced apoptosis in cancer cells

DATE-ISSUED: September 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mukhopadhyay; Tapas	Houston	TX		
Roth; Jack A.	Houston	TX		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE	CODE
Board of Regents, The University of Texas System	Austin	TX			02	

APPL-NO: 08/ 688613 [PALM]

DATE FILED: July 30, 1996

INT-CL: [06] A61 K 48/00, C12 N 15/79, C12 N 5/10

US-CL-ISSUED: 514/44; 435/320.1, 435/6, 435/69.1, 435/172.3, 435/375, 530/350.7

US-CL-CURRENT: 514/44; 435/320.1, 435/375, 435/6, 435/69.1

FIELD-OF-SEARCH: 514/44, 514/2, 435/235.1, 435/320.1, 435/6, 435/69.1, 435/172.3, 435/375, 530/350.7, 530/399, 424/93.1

PRIOR-ART-DISCLOSED:

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
95/12660	May 1995	WO	
WO 95/28948	November 1995	WO	

OTHER PUBLICATIONS

Tishler et al., "Microtubule-Active Drugs Taxol, Vinblastine, and Nocodazole Increase the Levels of Transcriptionally Active p53," Cancer Res., 55:6021-6025, 1995.

D'Amato et al., "2-Methoxyestradiol an Endogenous Mammalian Metabolite, Inhibits Tubulin Polymerization by Interacting at the Colchicine Site," Proceed. Natl. Acad. Sci. USA, 91:3964-3968, Apr. 1994.

Fotsis et al., "The Endogenous Oestrogen Metabolite 2-Methoxyoestradiol Inhibits Angiogenesis and Suppresses Tumor Growth," Nature, 368:237-239, 1994.

Seegers et al., "The Cytotoxic Effects of Estradiol-17 Beta, Catecholestradiols and Methoxyestradiols on Dividing MCF-7 and HeLa Cells," J. Steroid Biochem., 32(6):797-809, 1989.

Hurd et al., Hormonal Regulation of the p53 Tumor Suppressor Protein in T47D Human

Breast Carcinoma Cell Line, J. Steroid Biochem., 270(48):28507-28510, 1995.
Mukhopadhyay et al., Induction of Apoptosis in Human Lung Cancer Cells After Wild-Type p53 Activation by Methoxyestradiol, Oncogene, 14(3):379-384, 1997.
International Search Report, Dec. 2, 1997 (INGN:024P--).
Orkin et al. Report and Recommendations . . . Gene Therapy. NIHPress. Dec. 7, 1995. p. 1-40.
Miller et al. FASEB. vol. 9:190-199, Feb. 1995.
Marshall. Science.269:1050-1055, Aug. 1995.
Culver et al. TIG. 10(5):174-178, May 1994.
Hodgson. Exp Opin Ther. Patents. 5(5):459-468, 1995.
Fotsis et al. [Nature.368:237-239 (Mar. 1994)].
Hurd et al. [J. of Biol. Chem. 270(48):28507-10 (Dec. 1995)].
Kadkol et al. [Clinical and Investigative Medicine. 18(4)supp p.A668 #3877(Aug. 1995)].

Lottering et al (C34), Oct. 1, 1997.

ART-UNIT: 162

PRIMARY-EXAMINER: Chambers; Jasmine C.

ASSISTANT-EXAMINER: Hauda; Karen M.

ATTY-AGENT-FIRM: Arnold, White & Durkee

ABSTRACT:

The present invention details methods for the treatment of cancer. In particular, it concerns the induction of apoptosis of cancer cells following treatment with methoxyestradiol. 2-methoxyestradiol (2-MeOE.sub.2) increase wild-type p53 levels in a human non-small lung cancer cell lines associated with accumulation of cyclin dependent kinase inhibitor p21 WAF1/CIP1. Significant apoptotic cell death occurred after the drug treatment. Thus, 2-MeOE.sub.2 facilitates induction of p53-mediated apoptosis.

26 Claims, 6 Drawing figures

Int J Hematol 1998 Jul;68(1):29-43

Related Articles,

Links

Mechanisms involved in chemotherapy-induced apoptosis and their implications in cancer chemotherapy.

Kamesaki H.

Laboratory of Experimental Radiology, Aichi Cancer Center Research Institute, Nagoya, Japan.

The mechanisms by which chemotherapeutic agents kill neoplastic cells have been controversial. Recently, however, accumulated evidence has suggested that these agents exert their cytotoxic effects mainly by inducing apoptosis in tumor cells. This article reviews the findings of recent studies on the mechanisms by which chemotherapeutic agents induce apoptosis and their implications in cancer chemotherapy.

Apoptosis in murine tumors treated with chemotherapy agents.

Meyn RE, Stephens LC, Hunter NR, Milas L.

Department of Experimental Radiotherapy, University of Texas MD Anderson Cancer Center, Houston 77030, USA.

There is increasing attention directed to the hypothesis that apoptosis plays a role in the response to cancer treatment including chemotherapy. However, the evidence to support this hypothesis has come almost entirely from experiments conducted in cultured cell systems. To extend this hypothesis to the therapeutic setting it is necessary to address this critical question in tumors treated in vivo. We have therefore evaluated the extent of apoptosis induced in murine tumors treated in vivo with cancer chemotherapy agents. Seven different murine tumors, comprising a mammary adenocarcinoma (MCA-4), an ovarian adenocarcinoma (OCA-1), a lymphoma (LY-TH), three sarcomas (FSA, NFSA and SA-NH) and a squamous cell carcinoma (SSC-7), were examined 8 and 24 h after treatment with cisplatin or cyclophosphamide (CY). Apoptosis was scored by morphometric analysis of histological sections of the tumors. The results showed that MCA-4, OCA-1 and LY-TH had a significant apoptotic response to both cisplatin and CY, and the other tumors had essentially no apoptotic response. In addition, two of these tumors, MCA-4 and OCA-1, underwent apoptosis in response to adriamycin, 5-fluorouracil, Ara-C, etoposide, camptothecin and fludarabine. These observations demonstrate that apoptosis may be a feature of tumor response to chemotherapy in vivo, and illustrate the heterogeneity of apoptotic response amongst different tumor types and to different cytotoxic agents.

WEST**End of Result Set**

Generate Collection

Print

L1: Entry 1 of 1

File: USPT

Aug 10, 1999

US-PAT-NO: 5935801

DOCUMENT-IDENTIFIER: US 5935801 A

TITLE: Monoclonal antibody that detects apoptotic antigen

DATE-ISSUED: August 10, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Schlossman; Stuart Franklin	Newton Centre	MA		
Zhang; Chonghui	Brookline	MA		

ASSIGNEE-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Dana-Farber Cancer Institute	Boston	MA			02

APPL-NO: 08/ 623876 [PALM]

DATE FILED: March 29, 1996

INT-CL: [06] G01 N 33/53

US-CL-ISSUED: 435/7.91; 435/7.9, 435/29, 435/332, 435/336, 435/346, 530/388.2, 530/388.7, 436/538

US-CL-CURRENT: 435/7.91; 435/29, 435/332, 435/336, 435/346, 435/7.9, 436/538, 530/388.2, 530/388.7

FIELD-OF-SEARCH: 530/388.2, 530/387.1, 530/388.7, 435/29, 435/7.9, 435/7.91, 435/240, 435/26, 435/240.27, 435/332, 435/336, 435/346, 436/538

PRIOR-ART-DISCLOSED:

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
0510691A1	October 1992	EP	
0511202B1	June 1994	EP	
6109729	April 1994	JP	
9077794	March 1997	JP	
WO92/17193	October 1992	WO	
WO 00642	January 1995	WO	

OTHER PUBLICATIONS

Journal of Immunology, vol. 157, Nov. 1996, pp. 3980-3987, Zhang et al., "A mitochondrial membrane protein defined by a novel monoclonal antibody is preferentially detected in apoptotic cells."

Ajmani, A.K., M. Satoh, E. Reap, P.L. Cohen, and W.H. Reeves. 1995. Absence of autoantigen Ku in mature human neutrophils and human promyelocytic leukemia line (HL-60) cell and lymphocytes undergoing apoptosis. J. Exp. Med. 181:2049-2058.

Anderson, P., M. -L. Blue, C. O'Brien, and S. F. Schlossman. 1989. Monoclonal antibodies reactive with the T cell receptor chain: production and characterization using a new method. *J. Immunol.* 143: 1899-1904.

Barry, M. A., and A. Eastman. 1993. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. *Arch. Biochem. Biophys.* 300:440-450.

Boehmer, H. von. 1992. Thymic selection: a matter of life and death. *Immunology Today* 13:454-458.

Clarke, P. G. H. 1990. Developmental cell death: morphological diversity and multiple mechanisms. *Anal. Embryol.* 181:195-213.

Casciola-Rosen, L. A., G. Anhalt, and A. Rosen. 1994. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. *J. Exp. Med.* 179:1317-1330.

Cobbold, S. P., and H. Waldmann. 1981. A rapid solid-phase enzyme-linked binding assay for screening monoclonal antibodies to cell surface antigens. *J. Immunol. Meth.* 44:125-133.

Duke, R. C., R. Chervenak, and J. J. Cohen. 1983. Endogenous endonuclease-induced DNA fragmentation: an early event in cell-mediated cytolysis. *Proc. Natl. Acad. Sci. USA* 80:6361-6365.

Estus, S., W. J. Zaks, R. S. Freeman, M. Gruda, R. Bravo, and E. M. Johnson Jr. 1994. Altered gene expression in neurons during programmed cell death: Identification of c-Jun, as necessary for neuronal apoptosis. *J. Cell Biol.* 127:1717-1727.

Fernandez, P. A., R. J. Rotello, Z. Rangini, A. Doupe, H. C. A. Drexler, and J. Yuan. 1994. Expression of a specific marker of avian programmed cell death in both apoptosis and necrosis. *Proc. Natl. Acad. Sci. USA* 91:8641-8645.

Fiskum, G., S. W. Craig, G. L. Decker, and A. L. Lehninger. 1980. The cytoskeleton of digitonin-treated rat hepatocytes. *Pros. Natl. Acad. Sci. USA* 77:3430-3434.

Gougeon M. -L., and L. Montagnier. 1993. Apoptosis in AIDS. *Science* 260:1269-1270.

Griffiths, G., and H. Hoppeler. 1986. Quantitation in immunocytochemistry: correlation of immunogold labeling to absolute number of membrane antigens. *J. Histochem. Cytochem.* 34:1389-1398.

Hennet, T. G., Bertonni, C. Richter, and E. Peterhans. 1993a. Expression of Bcl-2 protein enhances the survival of mouse fibrosarcoma cells in tumor necrosis factor-mediated cytotoxicity. *Cancer Res.* 53:1456-1460.

Hennet, T. C. Richter, and E. Peterhans. 1993b. Tumor necrosis factor- α induced superoxide anion generation in mitochondria of L929 cells. *Biochem. J.* 289:587-592.

Hockenbery, T., G. Nunez, C. Millman, R. D. Schreiber, and S. J. Korsmeyer. 1990. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. *Nature* 348:334-346.

Itoh, N. S., Yonehara, A. Ishii, M. Yonehara, S. Mizushima, M. Sameshima, A. Hase, Y. Seto, and S. Nagata. 1991. The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. *Cell* 66: 233-243.

Jacobson, M. D., J. F. Burne, M. P. King, T. Miyashita, J. C. Reed, and M. C. Raff. 1993. Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA. *Nature* 361:365-369.

Kearney, J. F., A. Radbruch, B. Liesegang, and K. Rajewsky. 1979. A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines. *J. Immunol.* 123:1548-1550.

Kerr, J. F. R., A. H. Wyllie, and A. R. Currie. 1972. Apoptosis: a basic biological phenomenon with wide-ranging implication in tissue kinetics. *Br. J. Cancer* 26:239-257.

Kishimoto, H., C. D. Surn, and J. Sprent. 1995. Upregulation of surface markers on dying thymocytes. *J. Exp. Med.* 181:649-655.

Koopman, G., C. P. M. Reutelingsperger, G. A. M. Kuijten, R. M. J. Keehnen, S. T. Pals, and M. H. J. van Oers. 1994. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. *Blood* 84:1415-1420.

Kohler, G., and C. Milstein. 1975. Continuous cultures of fused cells secreting antibody of predefined specificity. *Nature* 256:495-497.

Krajewski, S., S. Tanaka, S. Takayama, M. J. Schibler, W. Fenton, and J. C. Reed. 1993. Investigation of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes. *Cancer Res.* 53:4701-4714.

Martin, S. J. 1993. Protein or RNA synthesis inhibition induces apoptosis of mature human CD4+ T Cell blasts. *Immunol. Lett.* 35:125-134.

Murgia, M., P. Pizzo, D. Sandona, P. Zanovello, R. Rizzuto, and F. di Virgilio. 1992. Mitochondrial DNA is not fragmented during apoptosis. *J. Biol. Chem.* 267:10939-10941.

Nunez, G., L. London, D. Hockenbery, M. Alexander, J. P. McKearn, and S. J. Korsmeyer. 1990. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. *J. Immunol.* 144:3602-3610.

Oehm, A., I. Behrmann, W. Falk, M. Pawlita, G. Maier, C. Klas, M. Li-Weber, S. Richards, J. Dhein, B. C. Trauth, H. Postinger, and P. H. Krammer. 1992. Purification and molecular cloning of the Apo-1 cell surface antigen, a member of the tumor necrosis factor/nerve growth factor receptor superfamily: Sequence identify with the Fas

antigen. J. Biol. Chem. 267:10709-10715.

Peitsch, M. C., B. Polzar, H. Stephan, T. Crompton, H. R. MacDonald, H. G. Mannherz, and J. Tschoop. 1993. Characterization of the endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis (programmed cell death). EMBO J. 12:371-377.

Robertson, M. J., T. J. Manley, G. Pichert, C. Cameron, K. J. Cochran, H. Levine and J. Ritz. 1995. Functional consequences of Apo-1/Fas (CD 95) antigen expression by normal and neoplastic hematopoietic cells. Leuk. Lymphoma 17:51-58.

Rotello, R. J., P. A. Fernandez, and J. Yuan. 1994. Anti-apoptosis and anti-engulfment: monoclonal antibodies reveal specific antigens on apoptotic and engulfment cells during chicken embryonic development. Development 120:1421-1431.

Smets, L. A., J. van den Berg, D. Acton, B. Top, H. van Rooij, and M. Verwijs-Janssen. 1994. BCL-2 expression and mitochondrial activity in leukemic cells with different sensitivity to glucocorticoid-induced apoptosis. Blood 5:1613-1619.

Steller, H., 1995. Mechanisms and genes of cellular suicide. Science 267:1445-1449.

Storrie, B., and E. A. Madden. 1990. Isolation of subcellular organelles. In Methods in Enzymology. vol. 182. Guide to protein purification. M. P. Deutscher, Editor, Academic Press, Inc., San Diego, CA 203-225.

Tepper, C. G., and G. P. Studzinski. 1992. Teniposide induces nuclear but not mitochondrial DNA degradation. Cancer Res. 52:3384-3390.

Thompson, C. B. 1995. Apoptosis in the pathogenesis and treatment of disease. Science 267:1456-1462.

Trauth, B. C., A. M. J. Klas S. Peters, P. M. Matzku, P. Moller, W. Falk, K. M. Debatin, and P. H. Krammer. 1989. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245:301-305.

Vaux, D., S. Cory, and J. Adams. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442.

Vayssiere, J. L., P. X. Petit, Y. Risler, and B. Mignotte. 1994. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc. Natl. Acad. Sci. USA 91:11752-11756.

Vukmanovic, S., and R. Zamoyska. 1991. Anti-CD3-induced cell death in T cell hybridomas: mitochondrial failure and DNA fragmentation are distinct events. Eur. J. Immunol. 21:419-424.

Wyllie, A. H. 1980. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature 284:555-556.

Yoneda, M., K. Katsumata, M. Hayakawa, M. Tanaka, and T. Ozawa. 1995. Oxygen stress induces an apoptotic cell death associated with fragmentation of mitochondrial genome, Biochem. Biophys. Res. Comm. 209:723-729.

Zamzami, N., P. Marchetti, M. Castedo, C. Zanin, J. L. Vayssiere, P. X. Petit, and G. Kroemer. 1995. Reduction in mitochondrial potential constitutes an early irreversible stop of programmed lymphocyte death in vivo. J. Exp. Med. 181:1661-1672.

Zhang C. H., M. J. Robertson, and S. F. Schlossman. 1995. A triplet of nuclease proteins (NP. sup. 42-50) is activated in human Jurkat cells undergoing apoptosis. Cell. Immunol. 165:161-167.

ART-UNIT: 164

PRIMARY-EXAMINER: Chan; Christina Y.

ASSISTANT-EXAMINER: Nolan; Patrick J.

ATTY-AGENT-FIRM: Alter; Mitchell E.

ABSTRACT:

A monoclonal antibody which specifically binds to an antigen on the membrane of mitochondria in apoptotic cells. The antigen is a 38 kD protein that is detectable in cells undergoing apoptosis and undetectable in normal cells. This selectivity of the monoclonal antibody provides a method of distinguishing between normal and apoptotic cells in a sample of human hemopoietic cell populations. A method for detecting and measuring cells undergoing apoptosis is also provided.

8 Claims, 18 Drawing figures

To identify the molecular markers for apoptotic cells, monoclonal antibodies were developed by immunizing mice with dying Jurkat cells. An

antibody, designated anti-7A6, was found to react preferentially with cells undergoing apoptosis and not with normal cells. The

antibody-defined molecule is a 38 kD protein localized to the membrane of mitochondria.